.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
QuintilesIMS
Baxter
Moodys
Dow
Merck
McKinsey
Chinese Patent Office
Cerilliant
Deloitte

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021711

« Back to Dashboard
NDA 021711 describes ABLAVAR, which is a drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ABLAVAR profile page.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

Summary for NDA: 021711

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength2440MG/10ML (244MG/ML)
Approval Date:Dec 22, 2008TE:RLD:No
Patent:6,676,929Patent Expiration:May 4, 2020Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength3660MG/15ML (244MG/ML)
Approval Date:Dec 22, 2008TE:RLD:No
Patent:6,676,929Patent Expiration:May 4, 2020Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021711

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20087,229,606► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20088,394,356► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 20085,362,475► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20085,362,475► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20088,017,105► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Chubb
UBS
McKesson
US Department of Justice
Argus Health
Accenture
Citi
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot